My watch list
my.bionity.com  
Login  

Lonza Expands Bioconjugation Facility and Announces Approval of Third Commercial ADC

24-Jul-2019

Lonza announced the start of expansion to its bioconjugation facility in Visp, Switzerland together with the successful commercial approval of a third antibody-drug-conjugate (ADC) produced at the site. Building on 12 years of experience in the exacting bioconjugation space, Lonza’s expansion will meet the development and manufacturing needs of pharma and biotech companies developing a new generation of therapies.

Lonza’s Visp site completed a successful FDA inspection for commercial manufacture of a recently approved ADC, the third to be commercialized from the bioconjugation facility. The existing capacity at the Visp facility will cover the current needs for production of this fast-tracked therapy.

Facts, background information, dossiers
  • Lonza
  • bioconjugation
  • bioconjugation facilities
More about Lonza
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE